This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Horizon Pharma plc
Drug Names(s): Prosaptide
Description: Prosaptide, a peptide derived from the human nerve growth protein prosaposin, is believed to be a peripherally acting analgesic, in contrast to central nervous system acting products that are typically associated with significant and sometimes potentially serious side effects. The side effects of central nervous system acting products such as opioids, anticonvulsants, and tricyclic antidepressants, which are frequently prescribed for neuropathic pain, include addiction, sedation, dizziness, and cardiac arrhythmia.
Horizon and Crealta
In December 2015, Horizon Pharma announced it has entered a definitive agreement to acquire Crealta Holdings for $510 million in cash. The acquisition is structured as an all cash purchase with no external financing necessary. The transaction, which has been approved by the boards of directors of both companies, is subject to the satisfaction of customary closing conditions and regulatory approvals, including antitrust approval in the United States.
In January 2016, Horizon announced that it has completed its acquisition of Crealta Holdings LLC for approximately $510 million in cash.
Partners: Ferring BV
Pink Sheet Savient re-evaluating prosaptide
Scrip Myelos Corp.
Scrip New Drugs for Pain
Pink Sheet Trademark Review
Additional information available to subscribers only: